Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Cantargia, Audiocast with teleconference, Q1'24

By Inderes5/21/2024, 1:00 PM
Cantargia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:00 - 14:59

Thanks a lot, and welcome to Cantargia's Q1 report 2024. It's a pleasure to present the progress we made with the company during the first quarter. So it's been a very good period and a good start of the year for us. During the first quarter, we presented the first clinical results from our CAN10 programme. Uh, and the results were good. So obviously we showed good safety. And we could also show receptor occupancy similar to what we expected from our model. Uh, but on a broader scale here, it actually means that Cantargia now has two clinical projects with recent clinical results, and this is a major step forward for the company. Uh, we also presented new clinical data on our lead program, nadunolimab, during the AACR. Uh, and around a very exciting finding that, not only can it have anti-tumor activity or proposed activity, but it can also reduce neuropathy, which is a very serious side effect of several chemotherapies and also ADCs. And there is going to be a presentation around this at ASCO in two weeks from now. So we very much look forward to updating you on that. Uh, at a later time point. Uh, also with nadunolimab, we got regulatory approval to start the phase 2b trial in pancreatic cancer. And after the period, we also had lots of new data being presented in various journals. And it was all related to systemic sclerosis today, which was published in a very high-impact journal. Data was presented on systemic sclerosis in a very high-impact journal. And finally, we also got a paper on the structure, function relationships and CAN10's mechanism of action, being published in another high-quality journal. And finally, just a few days ago, uh. And we'll come back to this later on. Uh, we had, let's say, clearance of one of our remaining patent appeals or oppositions. So there has been an appeal around one of our not a core patents, but an obviously important patent. But the third party withdrew that appeal, and that is obviously very good, because now we can continue to focus on nadunolimab and moving the product forward. So if we look into the status of a project and look at our pipeline. So not only is nadunolimab being developed quite broadly in cancer, the most mature data has been generated in pancreatic cancer, triple-negative breast cancer, and non-small cell lung cancer. And we'll come back to where we are in those programs. But the CAN10 program is also making progress, now still in clinical phase 1 but advancing quickly towards phase 2, starting next year. And the lead indications here are myocarditis and systemic sclerosis. And finally, we have our platform program CAN10 which consists of a number of antibodies that can be moved forward in the future. So in 2024 and 2025, there is a lot of things happening. So we have data coming up from two clinical programs, both CAN10 and additionally nadunolimab. And there are several other clinical milestones from the ongoing programs or new trials to start during 2024 and 2025. And there are publications and conferences coming up. So we made presentations at AACR. We're going to do a major presentation at ASCO. And I'm sure it's going to be much more and already rich with content. We have had three publications in impactful journals and presentations at conferences. And again, I expect much, much more during the rest of 2020 and next year. So now I would like to focus a little bit more on the content program to start with. It is a program where lots of things are happening both within the program but also in the environment around, which really increases the attention on this program. And the main reason is that CAN10 is a unique molecule because it's not only targeting specific cytokines; it's really targeting a whole family, the IL-1 family. And there is lots of evidence that the IL-1 family, which includes IL-1, IL-33, and IL-36, are driving inflammatory diseases by working together as a family. So there are lots of diseases. And we'll come back to that, showing that we can kind of regulate and operate together. And even more excitingly, there are lots of data showing that, for instance, IL-1 beta blockade, IL-6 blockade gives some signal of activity or even works in diseases where these systems are highly upregulated. But in most cases, it's not really translated into strong clinical efficacy. And there's more and more data being accumulated that it's because it's only a blocking of one of these compounds being done, which leads to a signal but not activity. But if you block them together, you will get some kind of additive or synergistic effect. And I think that's really triggering the interest around this compound. So basically what CAN10 is doing if you look at this slide is that it's binding to IL1RAP, which is a coreceptor IL-1 alpha IL-33 and IL-36. And it's blocking all of them by binding at one receptor. It blocks the binding of IL-1 receptor, IL-33 receptor, and IL-36 receptor, thereby shutting down the activity of this molecule. This molecule is completely. And if you look down here on this slide, this is really trying to illustrate what we're trying to achieve. If we have a biological system where IL-33 and IL-36 are all active and try to block one of the molecules, So if you're trying to block IL-1 with anakinra, IL-33 with the IL-33 receptor, or IL-36 with an IL-36 blocker, They are not very effective. But if you look at the blue line, you have a very potent inhibition which can turn. And this is really illustrating what we're trying to do in these diseases. And with the first in human studies ongoing, we're conducting a. A single ascending dose part, which means that you're applying single doses and it's going very well. We have not seen any safety signals and we have documented receptor occupancy. During Q3, we expect to start with subcutaneous administration in the pouch. So that's multiple dosing. And here we will now switch to psoriasis patients where there is a strong rationale for blocking all of these cytokines. So if you look at the right you can see in psoriasis which is represented by a gray bar here, you have an upregulation of IL-1 alpha, IL-1 beta, IL-36, so obviously blocking all of them at the same time could have a very interesting effect. And that's what we're trying to document. But clearly, psoriasis is an indication which is not of choice for the initial phase two. Where there are very active agents out there. And it would be a major commitment to start over. But in the future, who knows? But we've done animal models as well to prove that we can have efficacy in psoriasis models, which is only picked up with Cantargia's nardunolimab and not with anti-IL-1 beta, for instance. And in this multi-pot, we will do lots of biomarker analysis in addition to what's already been done in the set. And very quickly going through some of the preclinical data that was presented during the period. And this is in systemic sclerosis, where we take fibroblasts from patients. And what we can show here is that if we block the activity of these fibroblasts, which is part of the disease in systemic sclerosis, we can do that very efficiently with Cantargia's CAN10, even if we stimulate with TGF-beta or with IL-1 beta, IL-33 and IL-36. So this is clearly a very strong signal that we're on the right track. And we have previously presented animal models showing that, for instance, in this bleomycin model, that we have an active compound when it comes to skin fibrosis, which is on par with intravenous endothelin-1 blockers, which are used to some extent in systemic sclerosis. But to some extent those are limited by toxicity. So then moving over to nadunolimab, and here the news that was presented during the period was the neuropathy signal and neuropathy. It is a very serious medical condition which is unfortunately induced by several chemotherapies. And one central component in this chemotherapy-induced neuropathy relates to neuroinflammation, which is driven by the IL-1 system. And we have previously presented that we had a very low incidence of grade three neuropathies in these patients. In our pancreatic cancer trial where we studied Gemcitabine and Abraxane in combination with nadunolimab, so we had only a 1% incidence. Versus expected more than 10% from historical controls. But the signals that have now been taken forward. We can also see a significant signal if you look at the low-grade neuropathy. And that's something that will be presented at ASCO. And we have also done animal models. And we will present that work as well at ASCO. So I hope this will be something very exciting which will be disclosed in the near future. And then just to put this in perspective. So the new data will show that we can get rid of, or at least minimize, some very serious side effects of chemotherapy. But we've already previously shown that when we add nadunolimab to chemotherapy, there is a signal of activity both on survival and PFS. So the survival of 13.2 months, it's much, much better than you expect from, historical controls, which is more in the 9 to 10 months range. And to further strengthen those data, we also saw that patients with the highest IL1RAP have the strongest activity signal. So here the survival is more than 14 months. And this is very logical given that we have an antibody therapy targeting IL1RAP. More IL1RAP, very small tumors, and more antibodies can get in, bind and have activity in triple-negative breast cancer. Here we have a randomized phase 2b trial ongoing. It's going to be about two groups of 50 patients in the trial. We started with a lead-in phase which has been presented before. And again, we have good response rates, promising PFS, and survival. And we are very much looking forward to presenting randomized data later this year. So really, to summarize, nadunolimab shows lots of activity and it will be further explored. We have one randomized trial ongoing and two clinical trials starting this year. We have a pancreatic cancer phase 2b trial. And we also have an investigator-sponsored trial in leukemia, which is also funded by a very prestigious grant from the US Department of Defense. And there is more to come. So, before going into the financials, I would just highlight that Cantargia has a very strong IP position. We have composition of matter patents on both nadunolimab, which is expiring in 2045. We have a composition of matter patent expiring in 2041. We also have patents around the targets. And those patents have been the subject of several oppositions and appeals. But all of these, applications have ended up in a very favorable way for Cantargia. And the final appeal we had, in front of us, was relating to the solid tumor patent. But here, the third party who filed the appeal decided to withdraw, which means that all these patents are now valid and remain in force. So, this is obviously a very good step forward for Cantargia. So by that, I would like to hand over to Jörg Distler, who can present a little bit about the finances.

Jörg Distler
15:01 - 16:15

Thank you. You're on. Uh, and good afternoon, everybody. Uh, so this morning, we reported an almost 50% reduction in our operating expenses in the first quarter of 2024 compared with the same period last year. And the main reason for this is, uh, explained by R&D, where we are dropping, uh, 35 million, um, from, from our 238 million in the quarter. Um, the explanation for that is that, uh, we have, uh, two clinical studies actively recruiting in, in the period. And that's true for the triple negative breast cancer study for nadunolimab. And, uh, the first in human study for, for CAN10, um, driving cost. Um, and that is then compared to a full, uh, study program for nadunolimab, uh, one year ago. Also worth noting is that in the first quarter of 2023, we recorded relatively high cost for production of drug substance for nadunolimab. Um, and we've had no such, uh, investments, uh, incurred or reported in the in the first quarter this year.

Unknown 2
16:16 - 16:20

So our, um, our G&A expenses.

Jörg Distler
16:20 - 17:31

We constantly challenge those. And we've been able to reduce them by, um, a little more than a million Swedish kronor compared to Q1 2024. And that's, uh, we're very happy with that. But all in all, uh, we reported a loss in the period, uh, of 37 million SEK. Um, and that then also includes a positive impact from, uh, net financial items of 5 million Swedish kronor. So, um, we reported net available funds, and, uh, we keep reiterating that that is comprised of our cash and cash equivalents, uh, as well as what's defined as short term investments. So net available funds were 143 million, uh, in the end of the quarter, following a net burn of, uh, 52 million in the quarter. Um, and we expect that, uh, that liquidity, uh, will suffice to cover the ongoing activities for the next year. With that, I hand over to you again. Thank you.

Unknown 1
17:32 - 18:38

Thank you so much. So I would just like to conclude that the year has started well for Cantargia. But clearly we have very high expectations for the remaining part of 2024 with a rich news flow in pancreatic cancer, triple negative breast cancer, and the significant value inflection point of start of the leukemia trial with lots of data on Cantargia. So more phase 1 data being presented during 2024 as we make material progress and also the plan is to start phase 2b in 2025 and get the EU assigned in place. And we also have lots of other activities where we expect to present more data to give more clarity on where we're going. So by that, I really like to thank you for your attention. And if there are questions, I'd be very happy to respond to them. Now.

Operator
18:41 - 19:05

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanus from Red Eye. Please go ahead.

Unknown 3
19:06 - 19:26

Good afternoon. Thanks for taking my questions. Um, so I have a few. As you have a better runway now, will the readouts from the phase 2b trials of CAN10 and nadunolimab be covered? Um, during a financial plan.

Unknown 1
19:30 - 19:42

Yes, the plan is definitely to have TNBC and content data covered by this runway.

Unknown 3
19:44 - 20:13

Okay. A phrase in the Q1 report caught my attention. I wondered if you could comment on this. The board states that the company has good prospects of securing future financing, for example, through a licensing deal. I don't think I've seen that wording before. So, how have your business development discussions progressed, would you say, since before?

Unknown 1
20:17 - 20:38

So, I cannot comment in detail on our commercial discussions, but what it indicates is that we believe we will have good opportunities to continue financing the company, and partnerships are one way of doing that.

Unknown 3
20:42 - 21:04

Okay. Um, I was also wondering about what path forward you might take with the content, especially considering this interesting news in HS. And, um, what do you think would be the indication for the phase 2 study?

Unknown 1
21:08 - 22:23

So, you're absolutely right that there have been several reports in hydrogenated security, which is a very serious and quite common dermatological disease, both using blockade with IL-1 alpha/IL-1 beta through Mab and also from IL-4 to IL-6 blockade using specifically Mab. And clearly, if you combine those two datasets, it would really argue that context would be. A very active molecule. So, we are certainly incorporating that information into our development strategies. And we have ongoing clinical discussions and upcoming advisory boards here during the summer to further investigate, let's say, how a phase 2 trial and development plan would look like in the lead indication systemic sclerosis and myocarditis. But we are also including some other opportunities, and HS is one of those.

Unknown 3
22:26 - 22:28

Great.

Operator
22:33 - 22:40

The next question comes from Luisa Morgado from Van Kempen. Please go ahead.

Unknown 4
22:45 - 22:57

Hi Tim, thank you for taking my questions. I have a couple, uh, maybe first to start off with the Phase 1 trial. Could you perhaps provide a bit more detail on why the start was delayed?

Unknown 1
23:01 - 23:57

So I think there are several reasons why you try to estimate the timelines to start and then get everything in place. But one very clear aspect is that the trial is not fully financed yet with our cash on hand, and we are very seriously trying to get the best possible financing for this trial. And we have a number of. Interesting discussions on the next steps for financing the company. But, uh, we cannot start the trial until those have finished. And, uh, unfortunately, I cannot go into more details around this at this point in time.

Unknown 4
24:01 - 24:28

Okay. That was very clear. Thank you. And maybe moving on to Cantargia. Um, is there anything that you can already advance, as in terms of the phase 2 that you plan to start next year? And considering that, um, I think you mentioned in the report that the enrollment of the psoriasis patients will start in Q3. Will we already see any data for these patients this year or only next year?

Unknown 1
24:30 - 25:59

So, let's start with the second question on psoriasis. So we will start the treatment phase during Q3. And uh. It depends a little bit on how quickly all the biomarker initial analysis takes before you can get that type of data, but you can clearly get the safety data during this year. So hopefully, if we find anything material to communicate, we will do that from this trial, regardless if it's the third part and we have no reason to delay this type of communication. And then, uh, the first question was around phase 2. So clearly we are already now thinking ahead of starting a phase 2 in 1. One of the indications that I responded to previously, and we also want to start that trial as quickly as we possibly can after the MAD part. So we're targeting H2 2023. It will be tough to start already during H1, but, uh, as soon as we have safety data from the final med cohort, basically, we will go ahead and finalize protocols and go ahead with the submission.

Unknown 4
26:04 - 26:20

Okay. Very clear. And maybe one final question. In terms of operating expenses, how do you see this to develop throughout the rest of this year? Uh, will we see a further decrease as we've seen this quarter, or do you consider that this will stabilize from now on?

Jörg Distler
26:22 - 27:01

So, um, it's Patrick Heron. Thank you for that question, Luis. It's, uh, it's a very good one. So, um, as you said, we are working actively on establishing financing for the company, which then will help us, or enable the studies that we believe are important. Um, so, with that said, and if, and when that is secured, expenses will increase. What we have in the guiding for the runway is excluding those activities, and in that more hypothetical scenario, you can expect that the costs and burden will go down.

Unknown 4
27:04 - 27:05

Okay. Very helpful.

Unknown 2
27:06 - 27:07

So it's a little bit of a balance.

Jörg Distler
27:07 - 27:10

Uh, response to your question. I hope it answers.

Unknown 4
27:11 - 27:16

Yeah, very helpful. Thank you. That's all for me.

Operator
27:21 - 27:28

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Unknown 2
27:32 - 27:37

There are no further questions coming from the web either. So I hand over to you, Gian.

Gian
27:37 - 27:38

Yeah.

Unknown 1
27:38 - 28:10

So I can only conclude by saying we are extremely satisfied with how we have, let's say, started the year and the exciting data we have prepared. And we also very much look forward to continuing to deliver on all the opportunities we have at hand right now, as well as upcoming milestones and value inflection points. So, look forward to a very interesting 2024 and the second half of this year.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…